NORTHWESTERN UNIVERSITY
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM is a funding opportunity from NORTHWESTERN UNIVERSITY, up to 577634, closing December 31, 2029.
Dec 31, 2029
(1249d left)Overview
Glioblastoma (GBM) is an incurable brain tumor with a median overall survival of less than 15 months. The recent success of immunotherapy in extracranial malignancies has translated into trials for GBM. Despite its promise, immunotherapy's clinical efficacy has yet to be shown for GBM. The resistance to immunotherapy…